<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739529</url>
  </required_header>
  <id_info>
    <org_study_id>GPMOC101</org_study_id>
    <nct_id>NCT02739529</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer</brief_title>
  <official_title>Dose-dense Paclitaxel (Genexol®-PM) Once a Week in Combination With Carboplatin Every 3 Weeks for Gynecologic Cancer (Adult Solid Tumor): a Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks
      for gynecologic cancer (adult solid tumor): a phase I trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD)</measure>
    <time_frame>2 years</time_frame>
    <description>MTD was determined as the dose where more than 2 out of 6 subjects experienced DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended dose for the phase II study</measure>
    <time_frame>2 years</time_frame>
    <description>Determined as the recommended dose for a phase 2 study based on the adverse events and toxicities at each dose groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The dose limiting toxicity (DLT)</measure>
    <time_frame>2 years</time_frame>
    <description>Dose limiting toxicity (DLT) was defined as one of the following cases. NCI CTCAE V3.0 Grade 3 or more hypersensitivity despite premedication, Non-Hematological Toxicity other than nausea and vomiting, Hematological toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical/laboratory toxicities were monitored after the treatment, in order to evaluate safety and tolerance of the test drugs, and adverse events, which were maintained until visit on discontinuation date, were followed until recovered or stabilized</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genexol-PM</intervention_name>
    <description>Cremophor EL-free polymeric micelle of paclitaxel</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who aged 20 years or older and under 80 year old female

          2. Patients who were diagnosed histologically or cytologically or who were scheduled to
             reccur as an gynecologic cancer (epithelial ovarian cancer , fallopian tube cancer,
             primary peritoneal cancer, cervical cancer, uterine corpus cance, etc)

          3. Patients seemed appropriate for Paclitaxel and Carboplatin combination therapy for the
             treatment

          4. Patients whose ECOG performance score are 0-2

          5. Patients who have adequate blood, kidney and liver function on screening within 14
             days before the administration of the test drugs

               -  Hb ≥ 10g/dl: Patients with less than 10g/dl of hemoglobin level were not allowed
                  to use the test drugs unless they were recovered to 10g/dl or more.

               -  ANC ≥ 1500/mm3

               -  Platelet Count ≥ 100,000/mm3

               -  Serum AST and ALT ≤ 2.5 X ULN

               -  Serum ALP ≤ 2.5 X ULN

               -  Serum creatinine ≤ 2.5 X ULN

          6. Patients who participated voluntarily and who provided written informed consent before
             participating in the study

        Exclusion Criteria:

          1. Patients with the history of carcinoma in the past 5 years other than gynecologic
             cancer

          2. Patients who received radiotherapy at abdominal cavity or pelvis

          3. Patients who were receiving immunotherapy or hormone therapy

          4. Patients who received a major surgery other than debulking surgery within 2 weeks
             before the screening

          5. Patients with a past or present medical history of metastasis in central nervous
             system (CNS)

          6. Patients with NCI CTCAE V4.0 Grade 1 or more sensory or motor neuropathy

          7. Patients with severe comorbidities as follows

               -  medical or mental condition impossible to understand the clinical trial and
                  provide a written informed consent, based on the investigators' decision

               -  severe cardiovascular disease (such as ischemic heart disease requiring medical
                  therapy, myocardial infarction within the last 6 months, and grade 2~4 congestive
                  heart failure defined by New York Heart Association criteria)

               -  uncontrolled active infectious disease

               -  hypersensitivity to the test drugs or the vehicle

          8. Patients who participated in another study within 4 weeks before the screening

          9. Pregnant, lactating women or Patients who do not use contraceptive methods that can be
             medically accepted to the possibility of pregnancy in female volunteers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Man Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samyang Biopharmaceuticals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miryung Jin</last_name>
      <phone>+82-2-740-7289</phone>
      <email>miryung.jin@samyang.com</email>
    </contact>
    <investigator>
      <last_name>Yong man Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

